Aethon Therapeutics
PrivateLast Round
Series A
Jan 9, 2023
Total Funding Raised
$30M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Aethon Therapeutics is a biotechnology company that develops a cancer immunotherapy platform creating designed neoantigens to enhance cancer treatments and improve patient outcomes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aethon Therapeutics Comparables
Compare Aethon Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Clasp Therapeutics | 81% | |
| Alloy Therapeutics | 69% | |
| Light Horse Therapeutics | 66% |
For institutional investors. Book with your work email.
Aethon Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 9, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aethon Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apple Tree Partners | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 82% MoM, from 2.2K to 4K.
- Apr 27, 2025
Preclinical updates on KRAS-G12C immunotherapies to be shared at AACR 2025.
For institutional investors. Book with your work email.
Aethon Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aethon Therapeutics's valuation, stock price, and market status.
Is Aethon Therapeutics a public or private company?
Aethon Therapeutics is a private company.
What is the current stock price of Aethon Therapeutics?
Aethon Therapeutics is a private company, so its shares have no public market price. Caplight tracks Aethon Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aethon Therapeutics worth (valuation)?
Valuation information for Aethon Therapeutics is not publicly available.
Can I buy Aethon Therapeutics stock?
Aethon Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aethon Therapeutics's last funding round?
Aethon Therapeutics's most recent funding round was Series A on January 9, 2023.
Who are the main investors in Aethon Therapeutics?
Key investors in Aethon Therapeutics include Apple Tree Partners.
Will Aethon Therapeutics IPO soon?
No public IPO plans have been announced for Aethon Therapeutics.
How can I track Aethon Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Aethon Therapeutics's shares on secondary markets.